Ethics Approval for Amplia’s Accent-Mini Trial
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amplia Therapeutics (INNMF) received ethics approval for ACCENT-Mini, a trial of daily narmafotinib plus chemotherapy in metastatic pancreatic cancer. The trial will pair narmafotinib with gemcitabine and Abraxane at three selected Australian sites. Recruitment remains subject to site approvals.
The earlier ACCENT trial used intermittent narmafotinib dosing with chemotherapy and reported a 7.8% complete response rate, a 36% confirmed response rate and median overall survival of 11.1 months. It reported no significant change in tolerability compared with chemotherapy alone.
Amplia expects safety and pharmacokinetic data in late Q1/early Q2 2027. The data, which will include how the drug moves through the body, are intended to support an FDA protocol submission for a study designed to support a request for drug approval in pancreatic cancer.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointACCENT-Mini ethics approval advances testing of daily narmafotinib with gemcitabine and Abraxane in metastatic pancreatic cancer.
- Moderate pointACCENT median overall survival was 11.1 months with intermittent narmafotinib plus chemotherapy.
- Moderate pointACCENT confirmed response rate reached 36%, meeting the trial’s response goal and exceeding chemotherapy alone.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ACCENT-Mini data are expected in late Q1/early Q2 2027 to support Amplia’s FDA protocol submission for a registrational study.
- Minor pointACCENT complete response rate was 7.8% with intermittent narmafotinib plus chemotherapy.
- Minor pointACCENT tolerability showed no significant change compared with chemotherapy alone.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.ACCENT-Mini recruitment cannot begin until site approvals are finalized.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGHLIGHTS
- Ethics approval received for ACCENT-Mini, evaluating daily-dosed narmafotinib with gemcitabine and Abraxane in metastatic pancreatic cancer
- The trial builds on encouraging ACCENT results, including a
7.8% complete response rate and 11.1 months median overall survival - Safety and pharmacokinetic data from the study expected late Q1/early Q2 2027 to support FDA protocol submission for the registrational study
- ACCENT-mini is an important step in Amplia’s strategy to build the clinical data to position narmafotinib as a key component of combination therapies for difficult-to-treat cancers such as pancreatic cancer
Melbourne, Australia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that it has received ethics approval for its ACCENT-Mini trial in metastatic pancreatic cancer. Ethics approval is a key milestone in launching a clinical study, allowing patient recruitment to begin as soon as site approvals are finalised.
ACCENT-Mini will evaluate daily dosed narmafotinib in combination with the chemotherapies gemcitabine and Abraxane®. The trial builds on the encouraging results of the ACCENT trial, in which intermittently dosed narmafotinib plus chemotherapy improved outcomes across all measures of activity compared to chemotherapy alone. Notably, ACCENT delivered a complete response rate of
Three (3) clinical trial sites in Australia have been selected for ACCENT-Mini, and trial start-up activities at all sites are well advanced.
Safety and pharmacokinetic data from ACCENT-Mini are expected in late Q1/early Q2 2027. These data will form part of Amplia’s protocol submission to the FDA for the registrational study of narmafotinib in pancreatic cancer.
The ACCENT-Mini trial is an important step in Amplia’s strategy to build the clinical evidence for narmafotinib as a partner drug in combination treatments for hard-to-treat cancers, including pancreatic cancer. A major challenge in these cancers is that tumours often become resistant to both existing treatments and newer targeted medicines, such as KRAS inhibitors, limiting how effectively they work. Amplia believes narmafotinib has the potential to help overcome this challenge and make these treatments more effective for patients.
Amplia Therapeutics CEO and MD Dr Chris Burns commented: “We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options. Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini.”
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.
| Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 | Media Contact: Hannah Howlett, Titch Comms Hannah@titchcomms.com.au +61 450 648 064 U.S. Media: media@ampliatx.com |
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.
About Narmafotinib
Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has achieved its desired outcome in achieving a confirmed response rate of
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.